

Bioequivalence of olmesartan medoxomil versus hydrochlorothiazide in Korean subjects

Submission date 06/11/2012	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 08/11/2012	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 15/04/2014	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims:

This study tests the effect of two drugs, Olmetec Plus and Olmesartan in healthy Korean subjects.

Who can participate?

Healthy Korean volunteers, aged between 19 and 55 years.

What does the study involve?

Participants will be randomly allocated to one of two groups: A or B. During the first period, participants from group A will receive a reference drug (Olmetec Plus®) while participants from group B will receive a test drug (Oldesar Plus). After one week, the order will be reversed.

What are the possible benefits and risks of participating?

There is no direct benefit from participation in the study. Information learned from the study may help other people in the future. Participants may experience side effects related to the study drug, but this will be monitored carefully for any negative effects. Participants may experience discomfort during blood sampling, include faintness, swelling or bruising at the site from where blood is drawn.

Where is the study run from?

Clinical Trial Center, Seoul, Korea

When is study starting and how long is it expected to run for?

The study started in June 2010 and ran until 2011.

Who is funding the study?

Pacific Pharma Corporation, Seoul, Korea

Who is the main contact?

Dr. Min-Gul Kim
mgkim@jbctc.org

Contact information

Type(s)

Scientific

Contact name

Prof Min-Gul Kim

Contact details

20, Geonji-ro

Deokjin-gu

Jeonju

Korea, South

561-172

Additional identifiers

Protocol serial number

BIBE2010-23

Study information

Scientific Title

Pharmacokinetic properties and bioequivalence of olmesartan medoxomil versus hydrochlorothiazide in Korean subjects

Study objectives

The present study aims at comparing the pharmacokinetics of the original formulation of Olmesartan medoxomil / Hydrochlorothiazide and a same generic product. This is necessary to demonstrate bioequivalence to regulatory authorities.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Chonbuk National University Hospital Institutional Review Board, Jeonju, Republic of Korea, 28 June 2010, ref: CBBEIRB10-06-07

Study design

Open label randomised 2-treatment 2-period 2-sequence crossover design

Primary study design

Interventional

Study type(s)

Screening

Health condition(s) or problem(s) studied

Healthy Subjects

Interventions

To demonstrate the bioequivalence of a generic product containing phenazopyridine (one tablet x 100 mg) as test product Uropryrene® with the original formulation of phenazopyridine (one tablet x 100 mg) as reference product Pyridium®.

Both drugs will be administered orally in fasting state. All participants will be given each of the two drugs only once, in a cross-over design. The duration of washout period is 7 days.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Measurement of the pharmacokinetic parameters:

1. Serum Cmax
2. AUC

Key secondary outcome(s)

Measurement of the pharmacokinetic parameters - Serum Tmax

Completion date

17/07/2008

Eligibility

Key inclusion criteria

1. Healthy subjects aged 19 to 55
2. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests
3. Informed consent signed by the subject
4. Not pregnant female subject

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Use of any drugs known to significantly induce or inhibit drug-metabolizing enzymes within 1 month prior to dosing
2. Use of prescription or nonprescription drugs within 10 days prior to the first dose of study medication

3. Subjects who are known or suspected not to comply with the study directives
4. Participating in a bioequivalence study or other clinical study within 3 month preceding the first dose of study medication
5. Pregnant or nursing females
6. Subject who are hypersensitive to study medication or other related compounds
7. History of sensitivity to thiazide diuretics or sulfonamides
8. Acute or Chronic renal failure (creatinine clearance < 30mL/min), anuric patient
9. Severe Hepatic failure
10. Biliary atresia, biliary cirrhosis
11. Hyponatremia, hypokalemia, hypercalcemia, hyperuricemia patient
12. Addison's disease patient
13. Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption

Date of first enrolment

08/07/2008

Date of final enrolment

17/07/2008

Locations

Countries of recruitment

Korea, South

Study participating centre

20, Geonji-ro

Jeonju

Korea, South

561-172

Sponsor information

Organisation

Pacific Pharma Corporation (Korea, South)

Funder(s)

Funder type

Industry

Funder Name

Pacific Pharma Corporation (Korea, South)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2014		Yes	No